

## Instructions for Authors 2017

**General Policy.** ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works in the field of cancer research that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to peer-review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. All manuscripts submitted to AR are urgently treated with absolute confidence, with access restricted to the Managing Editor, the journal's secretary, the reviewers and the printers. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

**NIH Open Access Policy.** The journal acknowledges that authors of NIH-funded research retain the right to provide a copy of the published manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

**Copyright.** Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

**Format.** Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the "Shorter Oxford English Dictionary".

**Manuscripts.** Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double – spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding 4 printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) *First page* including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication "review", "clinical", "epidemiological", or "experimental" study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) *Abstract* not exceeding 150 words, organized according to the following headings: Background/Aim – Materials and Methods/Patients and Methods – Results – Conclusion; (c) *Introduction*; (d) *Materials and Methods/Patients and Methods*; (e) *Results*; (f) *Discussion*; (g) *Acknowledgements*; (h) *References*. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author's opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

**Figures.** All figures should appear at the end of the submitted document file. Once a manuscript is accepted all figures and graphs should be submitted separately in either jpg, tiff or pdf format and at a minimum resolution of 300 dpi. Graphs must be submitted as pictures made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Pages that include color figures are subject to color charges..

**Tables.** All tables should appear at the end of the submitted document file. Once a manuscript is accepted, each table should be submitted separately, typed double-spaced. Tables should be numbered with Roman numerals and should include a short title.

**References.** Authors must assume responsibility for the accuracy of the references used. Citations for the reference sections of submitted works should follow the standard form of "Index Medicus" and must be numbered consecutively. In the text, references should be cited by number. Examples: 1 Sumner AT: The nature of chromosome bands and their significance for cancer research. *Anticancer Res* 1: 205-216, 1981. 2 McGuire WL and Chamnes GC: Studies on the oestrogen receptor in breast cancer. In: *Receptors for Reproductive Hormones* (O' Malley BW, Chamnes GC (eds.)). New York, Plenum Publ Corp., pp 113-136, 1973.

***Nomenclature and Abbreviations.*** Nomenclature should follow that given in “Chemical Abstracts”, “Index Medicus”, “Merck Index”, “IUPAC -IUB”, “Bergey’s Manual of Determinative Bacteriology”, The CBE Manual for Authors, Editors and Publishers (6th edition, 1994), and MIAME Standard for Microarray Data. Human gene symbols may be obtained from the HUGO Gene Nomenclature Committee (HGNC) (<http://www.gene.ucl.ac.uk/>). Approved mouse nomenclature may be obtained from <http://www.informatics.jax.org/>. Standard abbreviations are preferable. If a new abbreviation is used, it must be defined on first usage.

***Clinical Trials.*** Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXXX (where XXXXXXXX represents the unique number, always prefixed by ‘NCT’). Please note that there is no space between the prefix ‘NCT’ and the number. Example: NCT00001789.

***Ethical Policies and Standards.*** ANTICANCER RESEARCH agrees with and follows the “Uniform Requirements for Manuscripts Submitted to Biomedical Journals” established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 ([www.icmje.org](http://www.icmje.org)). Microarray data analysis should comply with the “Minimum Information About Microarray Experiments (MIAME) standard”. Specific guidelines are provided at the “Microarray Gene Expression Data Society” (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

***Submission of Manuscripts.*** Please follow the Instructions for Authors regarding the format of your manuscript and references. Manuscripts must be submitted only through our online submission system at: <http://www.iar-submissions.com/login.html> In case a submission is incomplete, the corresponding Author will be notified accordingly. Questions regarding difficulties in using the online submission system should be addressed to: email: [journals@iar-anticancer.org](mailto:journals@iar-anticancer.org)

***Galley Proofs.*** Unless otherwise indicated, galley proofs will be sent to the corresponding Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Authors of online open access articles are entitled to a complimentary online subscription to Anticancer Research for the current year and all previous digital content since 2004. Requests should be addressed to the Editorial Office. Galley proofs should be returned corrected to the Editorial Office by email within two days.

### ***Specific information and additional instructions for Authors***

1. Anticancer Research (AR) closely follows the new developments in all fields of experimental and clinical cancer research by (a) inviting reviews on topics of immediate importance and substantial progress in the last three years, and (b) providing the highest priority for rapid publication to manuscripts presenting original results judged to be of exceptional value. Theoretical papers will only be considered and accepted if they bear a significant impact or formulate existing knowledge for the benefit of research progress.
2. Anticancer Research will consider the publication of conference proceedings and/or abstracts provided that the material submitted fulfils the quality requirements and instructions of the journal, following the regular review process by two suitable referees.
3. An acknowledgement of receipt, including the article number, title and date of receipt is sent to the corresponding author of each manuscript upon receipt. If this receipt is not received within 20 days from submission, the author should call or write to the Editorial Office to ensure that the manuscript (or the receipt) was not lost in the mail or during electronic submission.
4. Each manuscript submitted to AR is sent for review in confidence to two suitable referees with the request to return the manuscript with their comments to the Editorial Office within 12 days from receipt. If reviewers need a longer time or wish to send the manuscript to another expert, the manuscript may be returned to the Editorial Office with a delay. All manuscripts submitted to AR, are treated in confidence, without access to any person other than the Managing Editor, the journal’s secretary, the reviewers and the printers.

5. All accepted manuscripts are peer-reviewed and carefully corrected in style and language, if necessary, to make presentation clear. (There is no fee for this service). Every effort is made (a) to maintain the personal style of the author's writing and (b) to avoid change of meaning. Authors will be requested to examine carefully manuscripts which have undergone language correction at the pre-proof or proof stage.
6. Authors should pay attention to the following points when writing an article for AR:
  - The Instructions to Authors must be followed in every detail.
  - The presentation of the experimental methods should be clear and complete in every detail facilitating reproducibility by other scientists.
  - The presentation of results should be simple and straightforward in style. Results and discussion should not be combined into one section, unless the paper is short.
  - Results given in figures should not be repeated in tables.
  - Figures (graphs or photographs) should be prepared at a width of 8 or 17 cm with legible numbers and lettering.
  - Photographs should be clear with high contrast, presenting the actual observation described in the legend and in the text. Each legend should provide a complete description, being self-explanatory, including technique of preparation, information about the specimen and magnification.
  - Statistical analysis should be elaborated wherever it is necessary. Simplification of presentation by giving only numerical or % values should be avoided.
  - Fidelity of the techniques and reproducibility of the results, should be points of particular importance in the discussion section. Authors are advised to check the correctness of their methods and results carefully before writing an article. Probable or dubious explanations should be avoided.
  - Authors should not cite results submitted for publication in the reference section. Such results may be described briefly in the text with a note in parenthesis (submitted for publication by... authors, year).
  - The References section should provide as complete a coverage of the literature as possible including all the relevant works published up to the time of submission.
  - By following these instructions, Authors will facilitate a more rapid review and processing of their manuscripts and will provide the readers with concise and useful papers.
7. Following review and acceptance, a manuscript is examined in language and style, and galley proofs are rapidly prepared. Second proofs are not sent unless required.
8. Authors should correct their galley proofs very carefully and preferably twice. An additional correction by a colleague always proves to be useful. Particular attention should be paid to chemical formulas, mathematical equations, symbols, medical nomenclature etc. Any system of correction marks can be used in a clear manner, preferably with a red pen. Additions or clarifications are allowed provided that they improve the presentation but do not bring new results (no fee).
9. Articles submitted to AR may be rejected without review if:
  - they do not fall within the journal's policy.
  - they do not follow the instructions for authors.
  - language is unclear.
  - results are not sufficient to support a final conclusion.
  - results are not objectively based on valid experiments.
  - they repeat results already published by the same or other authors before the submission to AR.
  - plagiarism is detected by plagiarism screening services.

(Rejection rate (2016): 66%).
10. Authors who wish to prepare a review should contact the Managing Editor of the journal in order to get confirmation of interest in the particular topic of the review. The expression of interest by the Managing Editor does not necessarily imply acceptance of the review by the journal.
11. Authors may inquire information about the status of their manuscript(s) by calling the Editorial Office at +30-22950-53389, Monday to Friday 9.00-16.00 (Athens time), or by sending an e-mail to journals@iia-anticancer.org
12. Authors who wish to edit a special issue on a particular topic should contact the Managing Editor.
13. Authors, Editors and Publishers of books are welcome to submit their books for immediate review in AR. There is no fee for this service. (This text is a combination of advice and suggestions contributed by Editors, Authors, Readers and the Managing Editor of AR).

**Copyright© 2017** - International Institute of Anticancer Research (G.J. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.

# in vivo

- International Journal of Experimental and Clinical Pathophysiology and Drug Research
- Published bimonthly by the International Institute of Anticancer Research
- Available online only and open access (effective January 2017) with Stanford University HighWire Press

ISSN (online): 1791-7549

## General Policy

- IN VIVO is a multidisciplinary journal designed to bring together original high quality works and reviews on experimental and clinical biomedical research within the frames of human physiology, pathology and disease management. A special focus of the journal is the publication of works on: (a) Experimental development and application of new diagnostic procedures; (b) Pharmacological and toxicological evaluation of new drugs and drug combinations; (c) Clinical trials; (d) Development and characterization of models of biomedical research.
- The principal aim of IN VIVO is to provide prompt online publication for accepted articles, generally within 1-2 months from final acceptance.

## Editorial Office

International Institute of Anticancer Research, 1st km Kapandritiou-Kalamou Rd., P.O. Box 22, Kapandriti, Attiki 19014, Greece. Tel: +30 22950 52945, Fax: +30 22950 53389.

U.S. Branch: Anticancer Research Inc., USA, 111 Bay Avenue, Highlands, NJ, USA.

E-mail: journals@iiar-anticancer.org; IIAR websites: www.iiar-anticancer.org and www.iiarjournals.org

## Selection of Recent Articles

Effectiveness of Analogues of the GS-Nitroxide, JP4-039, as Total Body Radiation Mitigators. M.W. EPPERLY, J.R. SACHER, T. KRAINZ, X. ZHANG, P. WIPF, M. LIANG, R. FISHER, S. LI, H. WANG, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Wound Healing is Delayed in the ZSD Rat. M.A. SUCKOW, T.A. GOBBETT, R.G. PETERSON (*St. Paul, MN; Indianapolis, IN, USA*)

Active and Passive Immunization Against *Staphylococcus aureus* Periprosthetic Osteomyelitis in Rats. N.H.SØE, N.V. JENSEN, A.L. JENSEN, J. KOCH, S.S. POULSEN, G.B. PIER, H.K. JOHANSEN (*Copenhagen; Ballerup; Hørsholm, Denmark; Boston, MA, USA*)

Effective Mediastinal Lymphadenectomy for Esophageal Cancer Using Slender Tracheal Forceps in Prone Position Thoracoscopic Esophagectomy. M. NAKAJIMA, M. TAKAHASHI, Y. DOMEKI, H. SATOMURA, H. MUROI, M. KIKUCHI, H. OGATA, S. YAMAGUCHI, K. SASAKI, M. SAKAI, M. SOHDA, T. MIYAZAKI, H. KUWANO, H. KATO (*Mibu; Maebashi, Japan*)

A Model of the Development of Cisplatin Resistance in Human Small Cell Lung Cancer Xenografts. P.B. CAFFREY, G.D. FRENKEL, K.L. MCANDREW, K. MARKS (*California; Pittsburgh, PA; Newark, NJ, USA*)

Applicability of Commercially Available ELISA Kits for the Quantification of Faecal Immunoreactive Corticosterone Metabolites in Mice. K.S.P. ABELSON, O. KALLIOKOSKI, A.C. TEILMANN, J. HAU (*Copenhagen, Denmark*)

Gene Expression Analysis of Cultured Rat-Endothelial Cells after Nd: YAG Laser Irradiation by Affymetrix GeneChip Array. Y. MASUDA, S. YOKOSES, H. SAKAGAMI (*Saitama, Japan*)

Polymorphism in Murine mtATP8 Gene Correlates with Decreased Reactive Oxygen Species in Aging Hematopoietic Cells. C. ROOLF, C. KRETZSCHMAR, K. TIMMER, A. SEKORA, G. KNÜBEL, H.M. ESCOBAR, G. FUELLEN, S.M. IBRAHIM, M. TIEDGE, S. BALTRUSCH, S. MÜLLER, R. KÖHLING, C. JUNGHANSS (*Rostock, Germany*)

Induction of TGF- $\beta$  by Irradiation or Chemotherapy in Fanconi Anemia (FA) Mouse Bone Marrow is Modulated by Small Molecule Radiation Mitigators JP4-039 and MMS350. M.W. EPPERLY, D. FRANICOLA, T. DIXON, S. CAO, X. ZHANG, D. SHIELDS, H. WANG, P. WIPF, J.S. GREENBERGER (*Pittsburgh, PA, USA*)

Prognostic Impact of a Nutritional Index Including Muscle Volume in Stage 4 Colorectal Cancer. T. NAGATA, Y. NAKASE, K. NAKAMURA, A. SOUGAWA, S. MOCHIDUKI, S. KITAI, S. INABA (*Nara, Japan*)

Cell Pleomorphism and Cytoskeleton Disorganization in Human Liver Cancer. C.-C. CHENG, Y.-C.C. LAI, Y.-S. LAI, W.-T. CHAO, Y.-H. TSENG, Y.-H. HSU, Y.-Y. CHEN, Y.-H. LIU (*Changhua; Taichung; Kaohsiung; Hualien, Taiwan, ROC*)

The Effect of Induced Antibodies with Respect to Neutralization, Clearance Rate and Functional Activity in a Rabbit/Infliximab Model. M.L. HENRIKSEN, A. TEISNER, J. KJELDSEN, O. KALLIOKOSKI, J. HAU, S. WERNER, K. HANSEN (*Odense; Copenhagen, Denmark*)

Palliative Radiotherapy in Cancer Patients with Increased Serum C-reactive Protein Level. C. NIEDER, B. MANNSÅKER, A. DALHAUG, A. PAWINSKI, E. HAUKLAND (*Tromsø; Bodø, Norway*)

Simvastatin Inhibits Epithelial-to-Mesenchymal Transition Induction of HO-1 in Cultured Renal Proximal Tubule Cells. J.S. CLARK, A.J. CARTER, M. DIXIT, I. ARANY (*Jackson, MS, USA*)

**FREE SPECIMEN COPIES OF IN VIVO ARE AVAILABLE ON REQUEST**

MIC1/GDF15 as a Bone Metastatic Disease Biomarker. J. WINDRICOVA, R. FUCHSOVA, R. KUCERA, O. TOPOLCAN, O. FIALA, J. FINEK, D. SLIPKOVA ( <i>Prague, Czech Republic</i> ) .....	1501
Impact of Maintenance Therapy for Patients with Non-small Cell Lung Cancer in a Real-world Setting. K. YOH, Y. GOTO, Y. NAITO, K. KISHI, K. MORI, K. HOTTA, Y. HOSOMI, K. YAMADA, C. TANAI, Y. TOMIZAWA, A. INOUE, Y. HASEGAWA, M. NISHIO, Y. OHASHI, H. KUNITOH ( <i>Kashiwa; Tokyo; Koriyama; Okayama; Kurume; Gunma; Sendai; Nagoya, Japan</i> ) .....	1507
Thyroid Cancer in the Pediatric Age in Sicily: Influence of the Volcanic Environment. M. RUSSO, P. MALANDRINO, M. MOLETI, A. D'ANGELO, M. TAVARELLI, G. SAPUPPO, F. GIANI, P. RICHIUSA, S. SQUATRITO, R. VIGNERI, G. PELLEGRITI ( <i>Messina; Catania; Palermo, Italy</i> ) .....	1515
Comparison of Tyrosine Kinase Inhibitor <i>Versus</i> Mammalian Target of Rapamycin Inhibitor as Second-line Molecular-targeted Therapy for Patients with Poor-risk Metastatic Renal Cell Carcinoma. H. MIYAKE, S. IMAI, K. TAMURA, T. SUGIYAMA, H. FURUSE, S. OZONO, M. FUJISAWA ( <i>Hamamatsu; Kobe, Japan</i> ) .....	1523
Liver Resections for Colorectal Metastases in Patients Aged Over 75 Years. V. TRESKA, J. FICHTL, J. BRUHA, V. LISKA, S. KORMUNDA, J. FINEK ( <i>Pilsen, Czech Republic</i> ) .....	1529
Prognostic Factors and Treatment of Earlystage Small-cell Lung Cancer. L. KÄSMANN, L. BOLM, S. JANSSEN, D. RADES ( <i>Lübeck; Hannover, Germany</i> ) .....	1535
Errata .....	1539
Book Reviews .....	1541
Announcements .....	1546

Core Needle Biopsy Specimens Are More Appropriate than Surgical Specimens for Evaluating the Expression of Phosphoproteins as Biological Markers in Invasive Breast Cancer. H.-A. KIM, J.H. KIM, H.S. CHOI, Y.G. KIM, S.J. LEE, K.H. HAN, M.K. SEONG, H.S. SEOL, W.C. NOH ( <i>Seoul, Republic of Korea</i> ).....	1409
Surgical Resection for Pulmonary Metastasis from Pancreatic and Biliary Tract Cancer. T. TAGAWA, K. ITO, K. FUKUZAWA, T. OKAMOTO, A. YOSHIMURA, T. KAWASAKI, T. MASUDA, K. IWAKI, T. TERASHI, M. OKAMOTO, A. SHIROMIZU, A. MOTOHIRO, Y. MAEHARA ( <i>Oita; Fukuoka, Japan</i> ).....	1413
PD-L1 Expression Confers Better Prognosis in Locally Advanced Oral Squamous Cell Carcinoma. Y. KOGASHIWA, M. YASUDA, H. SAKURAI, M. NAKAHIRA, Y. SANNO, K. GONDA, T. IKEDA, H. INOUE, K. KUBA, S. OBA, J. ISHIKAWA, Y. ENOKI, S. MATSUMURA, K. MINAMI, Y. EBIHARA, M. SUGASAWA ( <i>Hidaka; Mitaka; Nihonmatsu, Japan</i> ) .....	1417
Familial Gastrointestinal Stromal Tumor with Germline <i>KIT</i> Mutations Accompanying Hereditary Breast and Ovarian Cancer Syndrome. Y. SEKIDO, S. OHIGASHI, T. TAKAHASHI, N. HAYASHI, K. SUZUKI, S. HIROTA ( <i>Tokyo; Osaka; Hyogo, Japan</i> ).....	1425
PD-L1 Expression Is a Prognostic Factor in Patients with Thoracic Esophageal Cancer Treated Without Adjuvant Chemotherapy. A. WAKITA, S. MOTOYAMA, H. NANJO, Y. SATO, K. YOSHINO, T. SASAKI, Y. KAWAKITA, J. LIU, K. IMAI, H. SAITO, Y. MINAMIYA ( <i>Akita, Japan</i> ) .....	1433
Non-Whipple Operations in the Management of Benign, Premalignant and Early Cancerous Duodenal Lesions. A. PAPALAMPROS, D. MORIS, A. PETROU, N. DIMITROKALLIS, I. KARAVOKYROS, D. SCHIZAS, I. DELLADETSIMA, T.N. PAPPAS, E. FELEKOURAS ( <i>Athens, Greece; Columbus, OH; Durham, NC, USA; Nicosia, Cyprus</i> ).....	1443
Statins Protect Against Acute RT-related Rectal Toxicity in Patients with Prostate Cancer: An Observational Prospective Study. I. PALUMBO, F. MATRONE, G. MONTESI, R. BELLAVITA, M. LUPATTELLI, S. SALDI, A. FRATTEGANI, E. ARENA, C. MARIUCCI, L. FALCINELLI, V. BINI, C. ARISTEI ( <i>Perugia, Italy</i> ) .....	1453
Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer. I.H. LEE, S. HWANG, S.J. LEE, B.W. KANG, D. BAEK, H.J. KIM, S.Y. PARK, J.S. PARK, G.S. CHOI, J.C. KIM, S.H. CHO, J.G. KIM ( <i>Daegu, Republic of Korea</i> ).....	1459
Multicenter Phase II Clinical Trial of Genexol-PM® with Gemcitabine in Advanced Biliary Tract Cancer. J.Y. KIM, Y.R. DO, H.S. SONG, Y.Y. CHO, H.M. RYOO, S.H. BAE, J.G. KIM, Y.S. CHAE, B.W. KANG, J.H. BAEK, M.K. KIM, K.H. LEE, K. PARK ( <i>Daegu; Ulsan, Republic of Korea</i> ).....	1467
The Clinical Efficacy of Enzalutamide in Metastatic Prostate Cancer: Prospective Single-center Study. G. CICERO, R. DE LUCA, P. DORANGRICCHIA, F. DIELI ( <i>Palermo, Italy</i> ) .....	1475
A Survival Score for Patients Assigned to Palliative Radiotherapy for Metastatic Bladder Cancer. D. RADES, L. MANIG, S. JANSSEN, S.E. SCHILD ( <i>Lübeck; Hannover, Germany; Scottsdale, AZ, USA</i> ).....	1481
Concurrent Chemotherapy Improves the Overall Survival of Patients Irradiated for Locally Recurrent Bladder Cancer. D. RADES, L. MANIG, S. JANSSEN, S.E. SCHILD ( <i>Lübeck, Germany; Scottsdale, AZ, USA</i> ).....	1485
Bevacizumab Combined with Chemotherapy in Children Affected by Hepatocellular Carcinoma: a Single-center Experience. M.D. DE PASQUALE, J.D.V. DE GOYET, L. MONTI, C. GRIMALDI, A. CROCOLI, A. CASTELLANO ( <i>Rome, Italy</i> ) .....	1489
A Single Institutional Analysis of Systemic Therapy for Unresectable or Recurrent Small Bowel Adenocarcinoma. S. MAKINO, H. TAKAHASHI, N. HARAGUCHI, J. NISHIMURA, T. HATA, C. MATSUDA, M. IKENAGA, K. MURATA, H. YAMAMOTO, Y. DOKI, M. MORI, T. MIZUSHIMA ( <i>Suita, Japan</i> ).....	1495

Multi-omics Profiling of Patients with Melanoma Treated with Nivolumab in Project HOPE. S. YOSHIKAWA, Y. KIYOHARA, M. OTSUKA, R. KONDOU, C. NONOMURA, H. MIYATA, A. IIZUKA, K. OHSHIMA, K. URAKAMI, T. NAGASHIMA, M. KUSUHARA, T. SUGINO, T. MOCHIZUKI, K. YAMAGUCHI, Y. AKIYAMA ( <i>Shizuoka; Tokyo, Japan</i> ) .....	1321
Adjuvant Chemotherapy with S-1 plus Cisplatin for Patients with Stage III Gastric Cancer After Curative Resection. K. MITA, H. ITO, E. OTA, K. TAKAHASHI, M. HASHIMOTO, H. ASAKAWA, T. HAYASHI, K. FUJINO ( <i>Chiba, Japan</i> ).....	1329
Prognostic Impact of Preoperative Albumin-to-Globulin Ratio in Patients with Colon Cancer Undergoing Surgery with Curative Intent. H. FUJIKAWA, Y. TOIYAMA, Y. INOUE, H. IMAOKA, T. SHIMURA, M. OKIGAMI, H. YASUDA, J. HIRO, S. YOSHIYAMA, S. SAIGUSA, M. KOBAYASHI, M. OHI, T. ARAKI, Y. MOHRI, M. KUSUNOKI ( <i>Tsu, Japan</i> ).....	1335
Efficacy of Conversion Surgery Following S-1 plus Cisplatin or Oxaliplatin Chemotherapy for Unresectable Gastric Cancer. M. FUKUCHI, E. MOCHIKI, T. ISHIGURO, T. OGURA, J. SOBAJIMA, Y. KUMAGAI, K. ISHIBASHI, H. ISHIDA ( <i>Kawagoe, Japan</i> ) .....	1343
KRAS Mutant Status May Be Associated with Distant Recurrence in Early-stage Rectal Cancer. M. SIDERIS, J. MOORHEAD, S. DIAZ-CANO, A. HAJI, S. PAPAGRIGORIADIS ( <i>London, UK</i> ) .....	1349
Enhanced Recovery After Surgery Programs for Laparoscopic Colorectal Resection May Not Need Thoracic Epidural Analgesia. K. ETO, I. KONDO, M. KOSUGE, M. OHKUMA, K. HARUKI, K. NEKI, H. SUGANO, R. HASHIZUME, K. YANAGA ( <i>Tokyo, Japan</i> ) .....	1359
Narcoleptic-like Episodes in a Patient Receiving Pegylated Interferon-alpha 2b: A Case Report and Review of Literature. B.O. LAWSON, H.T. KHONG ( <i>Scottsdale, AZ; Salt Lake City, UT, USA</i> ) .....	1365
Prediction of Postoperative Risks in Laparoscopic Partial Nephrectomy Using RENAL, Mayo Adhesive Probability and Renal Pelvic Score. S. BIER, S. AUFDERKLAMM, T. TODENHÖFER, S. KRUCK, K. SCHUSTER, S. RAUSCH, A. OTHMAN, M. NOTOHAMIPRODJO, K. NIKOLAOU, C. SCHWENTNER, A. STENZL, G. BIER, J. BEDKE ( <i>Tübingen, Germany</i> ) .....	1369
Expression of Indoleamine 2,3-Dioxygenase Gene Is a Feature of Poorly Differentiated Non-muscle-invasive Urothelial Cell Bladder Carcinomas. T. HUDOLIN, C. MENGUS, J. COULOT, Z. KASTELAN, A. EL-SALEH, G.C. SPAGNOLI ( <i>Zagreb, Croatia; Basel, Switzerland</i> ) .....	1375
Post-hepatectomy Refractory Ascites in Cirrhotic Patients with Hepatocellular Carcinoma: Risk Factor Analysis to Overcome this Problematic Complication. S. ITOH, H. UCHIYAMA, Y. IKEDA, K. MORITA, N. HARADA, K. SUGIMACHI, H. KAWANAKA, D. KORENAGA, T. YOSHIZUMI, K. TAKENAKA, Y. MAEHARA ( <i>Fukuoka, Japan</i> ) .....	1381
Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma. E. BATTOLLA, P.A. CANESSA, P. FERRO, M.C. FRANCESCHINI, V. FONTANA, P. DESSANTI, V. PINELLI, A. MORABITO, F. FEDELI, M.P. PISTILLO, S. RONCELLA ( <i>La Spezia; Genoa, Italy</i> ).....	1387
Elevated Metabolic Activity on <sup>18</sup> F-FDG PET/CT Is Associated with the Expression of EZH2 in Non-small Cell Lung Cancer. G. TOYOKAWA, K. TAKADA, T. OKAMOTO, Y. KOZUMA, T. MATSUBARA, N. HARATAKE, T. AKAMINE, S. TAKAMORI, M. KATSURA, F. SHOJI, R. HAMAMOTO, Y. ODA, Y. MAEHARA ( <i>Fukuoka; Tokyo, Japan</i> ) .....	1393
First-line Bevacizumab and Paclitaxel for HER2-negative Metastatic Breast Cancer: A French Retrospective Observational Study. V. DIERAS, S. POP, F. BERGER, M.-E. DUJARIC, P. BEUZÉBOC, L. ESCALUP, F.C. BIDARD, P.H. COTTU, C. LE TOURNEAU, S. PIPERNO-NEUMANN, V. LAURENCE, M. ROBAIN, B. ASSELAÏN, J.-Y. PIERGA ( <i>Paris, France</i> ) .....	1403

Vasohibin-1 as a Novel Prognostic Factor for Head and Neck Squamous Cell Carcinoma. C. TORII, Y. HIDA, M. SHINDOH, K. AKIYAMA, N. OHGA, N. MAISHI, Y. OHIRO, M. ONO, Y. TOTSUKA, Y. KITAGAWA, K. TEI, Y. SATO, K. HIDA ( <i>Sapporo; Miyagi, Japan</i> ) .....	1219
Safety and Tolerance of D,L-Methadone in Combination with Chemotherapy in Patients with Glioma. J. ONKEN, C. FRIESEN, P. VAJKOCZY, M. MISCH ( <i>Berlin; Ulm, Germany</i> ) .....	1227
Imaging and Pathology Correlations for Different Risk Stratification Models for Intermediate-risk Prostate Cancer. T. ELLIS-CALEO, J.V. HEGDE, S. BATH, S. MESKO, R. REITER, D. MARGOLIS, M. KAMRAVA ( <i>Los Angeles, CA; Irvine, CA; New York, NY, USA</i> ) .....	1237
Prevalence of Cervical Infection and Genotype Distribution of Human Papilloma Virus Among Females in Da Nang, Vietnam. S.N. VAN, M.N. KHAC, J. DIMBERG, A. MATUSSEK, A.J. HENNINGSSON ( <i>Da Nang, Vietnam; Jönköping; Stockholm, Sweden</i> ) .....	1243
Dose-dense Paclitaxel- and Carboplatin-based Neoadjuvant Chemotherapy Followed by Surgery or Concurrent Chemoradiotherapy in Cervical Cancer: a Preliminary Analysis. A. GADDUCCI, C. BARSOTTI, C. LALISCIA, S. COSIO, A. FANUCCHI, R. TANA, M.G. FABRINI ( <i>Pisa, Italy</i> ).....	1249
Parent of Origin and Prognosis in Familial Breast Cancer in Sweden. C. WENDT, A. LINDBLOM, B. ARVER, A. VON WACHENFELDT, S. MARGOLIN ( <i>Stockholm, Sweden</i> ) .....	1257
Biparametric <i>versus</i> Multiparametric MRI with Non-endorectal Coil at 3T in the Detection and Localization of Prostate Cancer. M. SCIALPI, E. PROSPERI, A. D'ANDREA, E. MARTORANA, C. MALASPINA, B. PALUMBO, A. ORLANDI, G. FALCONE, M. MILIZIA, L. MEARINI, M.C. AISA, P. SCIALPI, C. DE DOMINCIS, G. BIANCHI, A. SIDONI ( <i>Perugia; Aversa; Modena; Venice; Rome, Italy</i> ).....	1263
<sup>68</sup> Ga-PSMA Ligand PET/CT-based Radiotherapy for Lymph Node Relapse of Prostate Cancer After Primary Therapy Delays Initiation of Systemic Therapy. C. HENKENBERENS, C.A. VON KLOT, T.L. ROSS, F.M. BENGEL, H.-J. WESTER, H. KATJA, H. CHRISTIANSEN, T. DERLIN ( <i>Hannover; Garching, Germany</i> ) .....	1273
Assessment of Nutritional and Inflammatory Status to Determine the Prevalence of Malnutrition in Patients Undergoing Surgery for Colorectal Carcinoma. A. DANIELE, R. DIVELLA, I. ABBATE, A. CASAMASSIMA, V.M. GARRISI, E. SAVINO, P. CASAMASSIMA, E. RUGGIERI, R. DE LUCA ( <i>Bari, Italy</i> ) .....	1281
Mismatch Repair Protein Deficiency Is a Risk Factor for Aberrant Expression of HLA Class I Molecules: A Putative "Adaptive Immune Escape" Phenomenon. T. KUBO, Y. HIROHASHI, K. MATSUO, T. SONODA, H. SAKAMOTO, K. FURUMURA, T. TSUKAHARA, T. KANASEKI, M. NAKATSUGAWA, H. HIRANO, T. FURUHATA, I. TAKEMASA, T. HASEGAWA, T. TORIGOE ( <i>Sapporo, Japan</i> ) .....	1289
Development and Applicability of Integrative Tumor Response Assays for Metastatic Colorectal Cancer. Y.S. YOON, C.W. KIM, S.A. ROH, D.H. CHO, T.W. KIM, M.B. KIM, J.C. KIM ( <i>Seoul; Gyeonggi-do, Republic of Korea</i> ) .....	1297
Perfusion CT Changes in Liver Metastases from Pancreatic Neuroendocrine Tumors During Everolimus Treatment. M. D'ONOFRIO, S. CINGARLINI, S. ORTOLANI, S. CROSARA, R. DE ROBERTIS, P. VALLERIO, E. GREGO, V. CIARAVINO, A. RUZZENENTE, L. LANDONI, A. SCARPA, C. BASSI, G. TORTORA ( <i>Verona, Italy</i> ) .....	1305
Expression and Clinical Significance of Concomitant FAK/SRC and p-Paxillin in Mobile Tongue Squamous Cell Carcinoma. S. THEOCHARIS, I. KOTTA-LOIZOU, C. GIAGINIS, P. ALEXANDROU, E. DANAS, G. TSOUROUFLIS, N. TSOUKALAS, R.H.A. COUTTS, J. TASOULAS, J. KLIJANIENKO ( <i>Paris, France; Athens; Lemnos, Greece; London; Hatfield, UK</i> ) .....	1313



Identification of Methylation Profiles of Cancer-related Genes in Circulating Tumor Cells Population. A. LYBEROPOULOU, M. GALANOPOULOS, G. ARAVANTINOS, G.E. THEODOROPOULOS, E. MARINOS, E.P. EFSTATHOPOULOS, M. GAZOULI ( <i>Athens, Greece</i> ) .....	1110
Immunohistochemical Study of Vasculogenic Mimicry and Angiogenesis in Melanocytic Tumors of the Eye and the Periocular Area. K. SPILIOPOULOS, D. PESCHOS, A. BATISTATOU, I. NTOUNTAS, A. PAPOUDOU-BAI, A. ZIOGA, N. AGNANTIS, G. KITSOS ( <i>Ioannina; Athens, Greece</i> ) .....	1113
Failure of Inositol Trispyrophosphate to Enhance Highly Effective Radiotherapy of GL261 Glioblastoma in Mice. S. IYENGAR, D. SCHWARTZ ( <i>Hackensack, NJ, USA</i> ) .....	1121
Increased HGF Expression Induces Resistance to c-MET Tyrosine Kinase Inhibitors in Gastric Cancer. S.Y. AHN, J. KIM, M.A. KIM, J. CHOI, W.H. KIM ( <i>Seoul, Republic of Korea</i> ) .....	1127
Relationship Between $K_{trans}$ and $K_1$ with Simultaneous <i>Versus</i> Separate MR/PET in Rabbits with VX2 Tumors. K.H. LEE, S.K. KANG, J.M. GOO, J.S. LEE, G.J. CHEON, S. SEO, E.J. HWANG ( <i>Seoul; Seongnam; Incheon, Republic of Korea</i> ) .....	1139
Evodiamine Induces Cell Growth Arrest, Apoptosis and Suppresses Tumorigenesis in Human Urothelial Cell Carcinoma Cells. C.-S. SHI, J.-M. LI, C.-C. CHIN, Y.-H. KUO, Y.-R. LEE, Y.-C. HUANG ( <i>Taoyuan; Chiayi, Taiwan, ROC</i> ) .....	1149
Transient Receptor Potential Melastatin 7 as an Independent Prognostic Factor in Human Esophageal Squamous Cell Carcinoma. S. NAKASHIMA, A. SHIOZAKI, D. ICHIKAWA, S. HIKAMI, T. KOSUGA, H. KONISHI, S. KOMATSU, H. FUJIWARA, K. OKAMOTO, M. KISHIMOTO, E. KONISHI, E. OTSUJI ( <i>Kyoto, Japan</i> ) .....	1161
Elevated Preoperative Serum CEA Level Is Associated with Poor Prognosis in Patients with Hepatocellular Carcinoma Through the Epithelial–Mesenchymal Transition. M. YOSHIKAWA, Y. MORINE, T. IKEMOTO, S. IMURA, J. HIGASHIJIMA, S. IWAHASHI, Y. SAITO, C. TAKASU, S. YAMADA, D. ISHIKAWA, H. TERAOKU, A. TAKATA, T. YOSHIMOTO, M. SHIMADA ( <i>Tokushima, Japan</i> ) .....	1169
Comparative Analysis of a FRET-based PLK1 Kinase Assay to Identify PLK1 inhibitors for Chemotherapy. S.-B. SHIN, S.-U. WOO, Y.-J. LEE, H. YIM ( <i>Ansan, Republic of Korea</i> ) .....	1177
Embryonal Origin of MTSCC of Kidney May Explain its Morphological Heterogeneity: Diagnostic Impact of Genetic Analysis. D. BANYAI, F. VASTAG, M. YUSENKO, P. BUGERT, G. KOVACS ( <i>Pecs, Hungary; Heidelberg; Mannheim, Germany</i> ) .....	1185
Chemosensitizing Properties of $\beta$ -Caryophyllene and $\beta$ -Caryophyllene Oxide in Combination with Doxorubicin in Human Cancer Cells. S. DI GIACOMO, A. DI SOTTO, G. MAZZANTI, M. WINK ( <i>Rome, Italy; Heidelberg, Germany</i> ) .....	1191
Comparison of the Effects of Monastrol and Oxomonastrol on Human Hepatoma Cell Line HepG2/C3A. L.A. MARQUES, S.C. SEMPREBON, D. SARTORI, Â. DE FÁTIMA, L.R. RIBEIRO, M.S. MANTOVANI ( <i>Londrina; Belo Horizonte; Botucatu, Brazil</i> ) .....	1197
<i>Clinical Studies</i>	
Stable shRNA Silencing of Lactate Dehydrogenase A (LDHA) in Human MDA-MB-231 Breast Cancer Cells Fails to Alter Lactic Acid Production, Glycolytic Activity, ATP or Survival. N. MACK, E.A. MAZZIO, D. BAUER, H. FLORES-ROZAS, K.F.A. SOLIMAN ( <i>Tallahassee, FL, USA</i> ) .....	1205
Altered Levels of Serum Ceramide, Sphingosine and Sphingomyelin Are Associated with Colorectal Cancer: A Retrospective Pilot Study. D. SEPAROVIC, A.F. SHIELDS, P.A. PHILIP, J. BIELAWSKI, A. BIELAWSKA, J.S. PIERCE, A.L. TARCA ( <i>Detroit, MI; Charleston, SC, USA</i> ) .....	1213

Treatment of Hematological Malignancies with Glycyrrhizic Acid. B.J. HOSTETLER, O.N. UCHAKINA, H. BAN, R.J. MCKALLIP ( <i>Macon, GA, USA</i> ) .....	997
Antimetastatic Efficacy of the Combination of Caffeine and Valproic Acid on an Orthotopic Human Osteosarcoma Cell Line Model in Nude Mice. K. IGARASHI, K. KAWAGUCHI, T. KIYUNA, T. MURAKAMI, N. YAMAMOTO, K. HAYASHI, H. KIMURA, S. MIWA, H. TSUCHIYA, R.M. HOFFMAN ( <i>San Diego, CA, USA; Kanazawa, Japan</i> ) .....	1005
Mast Cells in Mammary Carcinogenesis: Host or Tumor Supporters? A.I. FAUSTINO-ROCHA, A. GAMA, M.J. NEUPARTH, P.A. OLIVEIRA, R. FERREIRA, M. GINJA ( <i>Vila Real; Aveiro; Gandra; Porto, Portugal</i> ) .....	1013
Induction of Apoptosis in Human Oral Keratinocyte by Doxorubicin. H. SAKAGAMI, N. OKUDAIRA, Y. MASUDA, O. AMANO, S. YOKOSE, Y. KANDA, M. SUGURO, T. NATORI, H. OIZUMI, T. OIZUMI ( <i>Sakado; Kanagawa, Japan</i> ) .....	1023
Peroxiredoxin Expression of Human Osteosarcoma Cells Is Influenced by Cold Atmospheric Plasma Treatment. D. GÜMBEL, N. GELBRICH, M. NAPP, G. DAESCHLEIN, A. KRAMER, A. SCKELL, M. BURCHARDT, A. EKKERNKAMP, M.B. STOPE ( <i>Greifswald; Berlin, Germany</i> ) .....	1031
The Histogenesis of the Third Pathway of Colonic Carcinogenesis in Rats. C.A. RUBIO ( <i>Stockholm, Sweden</i> ) ....	1039
Significance and Function of MicroRNA-7 in Oesophageal Squamous Cell Carcinoma. K. HARA, T. MIYAZAKI, T. YOKOBORI, T. YOSHIDA, Y. KUMAKURA, H. HONJYO, M. SAKAI, M. SOHDA, M. FUKUCHI, H. KUWANO ( <i>Maebashi, Japan</i> ) .....	1043
Targeting the Unfolded Protein Response as a Potential Therapeutic Strategy in Renal Carcinoma Cells Exposed to Cyclosporine A.S. BODEAU, C. SAUZAY, R. NYGA, C. LOUANDRE, V. DESCAMPS, C. FRANÇOIS, C. GODIN, G. CHOUKROUN, A. GALMICHE ( <i>Amiens, France</i> ) .....	1049
Next-generation Sequencing for microRNA Profiling: MicroRNA-21-3p Promotes Oral Cancer Metastasis. H.-H. TSENG, Y.-K. TSENG, J.-J. YOU, B.-H. KANG, T.-H. WANG, C.-M. YANG, H.-C. CHEN, H.-H. LIU, P.-F. LIU, L.-P. GER, K.-W. TSAI ( <i>Kaohsiung; Taipei; Changhua; Tainan; Pingtung, Taiwan, ROC</i> ) .....	1059
Additive Interaction of Cisplatin and Histone Deacetylase Inhibitors Combined Treatment in Rhabdomyosarcoma Cells – An Isobolographic Analysis. A. JARZĄB, J.J. ŁUSZCZKI, M. GUZ, E. GUMBAREWICZ, K. POLBERG, A. STEPULAK ( <i>Lublin, Poland</i> ) .....	1067
Induced Pluripotent-stem-cell Related Genes Contribute to De-differentiation in Oral Squamous Cell Carcinoma. D. TAKEDA, T. HASEGAWA, T. UEHA, E. IWATA, R. HARADA, A. SAKAKIBARA, T. KAWAMOTO, T. MINAMIKAWA, Y. SAKAI, T. KOMORI ( <i>Kobe, Japan</i> ) .....	1075
Clinical Significance of <i>FANCD2</i> Gene Expression and its Association with Tumor Progression in Hepatocellular Carcinoma. H. KOMATSU, T. MASUDA, T. IGUCHI, S. NAMBARA, K. SATO, Q. HU, H. HIRATA, S. ITO, H. EGUCHI, K. SUGIMACHI, H. EGUCHI, Y. DOKI, M. MORI, K. MIMORI ( <i>Beppu; Suita, Japan</i> ) .....	1083
Quantitative Structure–Cytotoxicity Relationship of Chalcones. H. SAKAGAMI, Y. MASUDA, M. TOMOMURA, S. YOKOSE, Y. UESAWA, N. IKEZOE, D. ASAHARA, K. TAKAO, T. KANAMOTO, S. TERAOKUBO, H. KAGAYA, H. NAKASHIMA, Y. SUGITA ( <i>Sakado; Tokyo; Kanagawa, Japan</i> ) .....	1091
Global MicroRNA Expression Profiling Identifies Unique MicroRNA Pattern of Radioresistant Glioblastoma Cells. J. ONDRACEK, P. FADRUS, J. SANA, A. BESSE, T. LOJA, M. VECERA, L.RADOVA, M. SMRCKA, P. SLAMPA, O. SLABY ( <i>Brno, Czech Republic</i> ) .....	1099